Our Approach

Revolutionizing Brain Health

BetterLife is developing non-hallucinogenic psychedelic derived compounds that can repair, rewire and heal the brain.

The New Paradigm and its Challenges

Psychedelics have emerged as a new paradigm in treatment of neurological and psychiatric disorders. A key property of psychedelics is their neuroplastogenic activity.

A neuroplastogen is a compound that induces new neuronal growth - enabling the brain to rewire, repair and heal itself.

Psychedelics are potent neuroplastogens when given at full doses, but they have several challenges related to their side effects, accessibility and complicated treatment protocols. Firstly, they have unwanted side effects like hallucinations, cardiac damage risks and other side effects. Secondly, being controlled substances, patient self-administration at home is illegal in most countries. Thirdly, treatment is restricted to specialized clinics with monitoring under special treatment protocols which require in-clinic time of 8 to 12 hours in the presence of two mental healthcare professionals.

The BetterLife Solution

BetterLife is developing psychedelic-derived compounds that are potent neuroplastogens but:

Do not cause hallucinations

Do not have cardiac safety issues

Are not a controlled substance

Patient can self-administer without needing specialized clinics and treatment protocols

Working together to Build a BetterLife for all.

REACH US

Burdens call for alternatives in the landscape of options ….

Challenges Facing All Stakeholders in Mental Healthcare

People

Are struggling with increased occurrences of mental health issues

Health Providers

Are challenged to keep pace with more demands for better solutions

Insurance Providers

Are strained from pressures due to increasing number of patients

Governments

Are logging higher health care costs from rising mental health problems

Adult with Depression

0 %

Do Not Receive Mental Health Treatment²

Covid Mental Strain

0 %

US Adults Are Dealing with Anxiety & Depression¹

Mental Health Spending

$ 0 Billion

Increase In Anxiety & Depression In Adults³

Pipeline and Indications Program

We are developing first-in-class, 2nd Generation, non-hallucinogenic, patient-centric therapeutics to treat various mental and neurological disorders with high unmet need

Our commitment, from inception to reception, is to deliver patient-centric medicines rooted on solid pharmacological principles and processes that deliver results.

The New Paradigm and it Challenges

We are developing first-in-class, 2^nd Generation, non-hallucinogenic, patient-centric therapeutics to treat various mental and neurological disorders with high unmet need

Compound Name: BETR-001

Product Name: E559 [proprietary 2-bromo-LSD compound]

Delivery: Oral, Capsule

Description: AA first-in-class, non-hallucinogenic, second-generation LSD derivative.

Indications: MDD, Anxiety, Neuropathic Pain

Patents: Issued and Pending

Compound Name: BETR-002

Product Name: Dihydrohonokiol-B (DHH-B)

Delivery: Oral Capsule

Description: A derivative of hydrohonokiol, a known anxiolytic compound.

Indications: Benzodiazepine Dependency, Anxiety, Neurodegenerative disorders

Patents: Pending

Pipeline
Program	Discovery	Preclinical	IND	Phase I	Phase II	Phase III
Major Depressive Disorder BETR-001
Anxiety Disorder BETR-001
Neuropathic Pain BETR-001
Benzodiazepine Dependency BETR-002

References

https://www.nature.com/articles/d41586-021-00175-z
https://mhanational.org/sites/default/files/2021%20State%20of%20Mental%20Health%20in%20America_0.pdf
https://finance.yahoo.com/news/why-mental-health-care-in-america-is-so-shoddy-183448311.html

Clinical Process

Study Design

Customized & Protocol Based

Drug Development

Proactive & Data Driven

Trial Execution

Transparent & Compliant

Regulatory Submission

Complete & Timely